Last updated on July 2019

Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Exudative retinopathy
  • Age: - 16 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Coats disease confirmed by fundus examination and fluorescein angiography
  • Stage 2 or 3 at the fundus (Shields classification)
  • Naive to any eye treatment on the eye affected by Coats disease

Exclusion Criteria:

  • Other ocular pathology on the eye affected by Coats' disease
  • Bilateral forms of the disease
  • History of hypersensitivity to bevacizumab
  • History of hypersensitivity to products of Chinese hamster ovary cells or other recombinant human or humanized antibodies
  • Allergic reaction in a previous fluorescein retinal angiogram
  • Pregnancy or breastfeeding
  • Active or suspected periocular infection
  • Contraindication to treatments used for general anesthesia and morphine derivatives
  • Cardiovascular, haemorrhagic and gastrointestinal risks
  • Premature baby who has not reached the correct age of 37 weeks

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.